GoAI
Get started
Context Therapeutics Inc. logo

Context Therapeutics Inc.

CNTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.5001

−$0.0196 · -3.77%

Aug 21, 4:00 PM ET

Pre-market

$0.48

−$0.0201 · -4.02%

Aug 24, 7:40 AM ET

CNTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

40

Expensive

Momentum

29

Weakening

Sentiment

47

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Martin A. Lehr
Listed since
Oct 20, 2021
Employees
15

Market position

Day range

Current $0.5001

52-week range

Current $0.5001

Open
$0.5275
Previous close
$0.5197
Volume
1.75M
0.82× average
Average volume
2.12M
Average daily volume
Market cap
45.95M USD
Beta
1.75
Market reference 1
50-day average
$0.6199
-19.33% below average
200-day average
$1.675
-70.14% below average

Financials

Financial statements

Income trends

Operating income

−39.7M USD-32.68%

Net income

−36.12M USD-35.17%
Income trends across reported periods−7.53M USD−19.23M USD−30.93M USD−42.63M USDOperating income, FY2021: −10.53M USDOperating income, FY2022: −15.38M USDOperating income, FY2023: −25.07M USDOperating income, FY2024: −29.92M USDOperating income, FY2025: −39.7M USDNet income, FY2021: −10.46M USDNet income, FY2022: −14.84M USDNet income, FY2023: −23.96M USDNet income, FY2024: −26.73M USDNet income, FY2025: −36.12M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −10.53M USD. Operating income FY2022 −15.38M USD. Operating income FY2023 −25.07M USD. Operating income FY2024 −29.92M USD. Operating income FY2025 −39.7M USD. Net income FY2021 −10.46M USD. Net income FY2022 −14.84M USD. Net income FY2023 −23.96M USD. Net income FY2024 −26.73M USD. Net income FY2025 −36.12M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development31.86M USD22.7M USD17.78M USD7.09M USD3.81M USD
Selling, general, and administrative7.85M USD7.22M USD7.29M USD7.79M USD3.63M USD
Operating expenses39.7M USD29.92M USD25.07M USD15.38M USD10.53M USD
Interest income3.38M USD3.2M USD1.16M USD547.27K USD64.24 USD
Interest expense———547.27K USD64.24K USD
Depreciation and amortization16.25K USD10.88K USD12.04K USD9.27K USD−3.09M USD
Operating income−39.7M USD−29.92M USD−25.07M USD−15.38M USD−10.53M USD
Net income−36.12M USD−26.73M USD−23.96M USD−14.84M USD−10.46M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-12.43%
11 comparable reports
Latest EPS result
-0.15
Estimate -0.09 · Miss by 62.80%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.09-0.14-0.19Q1 '25BeatQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.04, estimate -0.05, surprise +20.00%, Beat. Q2 2025, reported May 7, 2025: actual -0.05, estimate -0.05, surprise 0.00%, Met estimate. Q3 2025, reported Aug 6, 2025: actual -0.09, estimate -0.06, surprise -50.00%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.1, estimate -0.09, surprise -11.11%, Miss. Q1 2026, reported Mar 19, 2026: actual -0.14, estimate -0.11, surprise -27.27%, Miss. Q2 2026, reported May 6, 2026: actual -0.09, estimate -0.12, surprise +25.00%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.15, estimate -0.092, surprise -62.80%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.1, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates137.15K-434.15K-1.01M-1.58MQ1 '24No estimateQ1 '26Estimate
Q1 2024, reported Mar 21, 2024: actual 18.95K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 19, 2026: actual —, estimate -1.46M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

6 ratings
Strong buy00%
Buy6100%
Hold00%
Sell00%
Strong sell00%

CNTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CNTX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.69M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
1.19M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
454.68K
Weight
0.00%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
317.59K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
312.29K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
164.88K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
60.26K
Weight
0.00%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
iShares Russell 2500 ETF logoiShares Russell 2500 ETFSMMD
Market value
23K
Weight
0.00%
AUM
3.85B USD
Expense ratio
0.23%
Price / 1D
$91.86+0.58%

Continue in GoAI

Research CNTX

research.disclaimer